An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Astex Pharmaceuticals; Otsuka Pharmaceutical
- 01 Jul 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 16 Apr 2019 This trial has been discontinued in Austria, according to European Clinical Trials Database.
- 29 Jun 2018 New trial record